RCMI Coordinating Center (RCMI CC) Header Logo

Huan Xie

TitleDr.
Faculty RankProfessor
InstitutionTexas Southern University
DepartmentDepartment of Pharmaceutical Sciences
Address3100 Cleburne Street, Gray Hall 219
College of Pharmacy and Health Sciences
Texas Southern University
Houston TX 77004
Phone7133134340
Email
ORCID ORCID Icon0000-0002-0591-5619 Additional info
vCardDownload vCard

    Collapse Affiliation 

    Collapse Biography 
    Collapse education and training
    North Carolina State University, RaleighPh.D.10/2004Chemistry
    Fudan University, ShanghaiB.S.06/1999Chemistry
    Collapse awards and honors
    2009Seed Grant, Texas Southern University
    2010 - 2011Pharmaceutics Research Grant, Pharmaceutical Research and Manufacturers of America Foundation
    2011 - 2012Research Centers in Minority Institutions Translational Research Network Small Grant , NIH
    2012AACR 2012 Minority-Serving Institution Faculty Scholar in Cancer Research Award, AACR
    2012 - 2016Support of Competitive Research (SCORE) Research Continuance Award (SC3), NIH-NIGMS
    2015BUILDing SCHOLARS Summer Sabbatical Award, The University of Texas at El Paso
    2015Faculty Excellence Award-Scholarly Research/Creative activities Award, Texas Southern University
    2016AACR 2016 Minority-Serving Institution Faculty Scholar in Cancer Research Award, AACR
    2014 - 2019Research Centers in Minority Institutions Program (G12), NIMHD
    2018 - 2023Core Facilities Support Awards (CFSA), Cancer Prevention Research Institute of Texas (CPRIT)
    2020 - 2025Research Centers in Minority Institutions Program (U54), NIMHD
    2022 - 2027NCI Experimental Therapeutics (NExT) Program Chemical Biology Consortium (CBC), NCI
    2021 - 2023Cancer Therapeutics Training Program (CTTP), Cancer Prevention Research Institute of Texas (CPRIT)

    Collapse Overview 
    Collapse overview
    I have a strong background in drug characterization, formulation, novel delivery systems, pharmacokinetics and nanotechnology, with a focus on preclinical drug development. I have the specific training, expertise, leadership, and motivation to conduct the proposed project. Currently, I serve as the Founding Director of the Institute of Drug Discovery and Development (iD3) at TSU, which is an NCI-designated subcontractor to provide service for investigators cross the United States. I am the PI and Director of the Research Centers in Minority Institutions (RCMI) Center for Biomedical and Minority Health Research (CBMHR) supported by NIMHD. I am also co-Director of the Gulf Coast Consortia (GCC) Center for Comprehensive PK/PD and Formulation (CCPF) which is funded by the Cancer Prevention & Research Institute of Texas, known as CPRIT. I had four years of industrial experience as Senior Research Scientist working on silica/gold nanoshells for photothermal ablation cancer therapy, which has been used in several cancer clinical trials. Since joining Texas Southern University in 2008, I have successfully completed over 60 research projects, taught over 1000 Pharm.D. students, and personally mentored 10 research scientists/postdoctoral fellows, and over 30 Ph.D., Pharm.D., and undergraduate students, most of whom were underrepresented minorities (URM). I have served as Program Director of the Graduate Program of Pharmaceutical Sciences (GPPS) since 2020, focusing on mentoring the next generation of URM scientists in the field of Pharmaceutics. These trainees were highly sought by employers, such as the FDA, drug companies, hospitals, and academia. As PI or co-Investigator on several NIH- and private agency-funded grants, I laid the groundwork for the proposed research by developing novel analytical methods, advanced drug formulations, and delivery systems and establishing pharmacokinetic and biodistribution profiles. In addition, I successfully administered funded projects (e.g. staffing, research progress, budget, etc.), collaborated with other researchers from institutions across the U.S., generated patents, and produced peer-reviewed publications from these projects (see select list below). These previous experiences made me aware of the importance of frequent communication among project members, and of constructing a realistic program plan, research design, timeline, and budget.

    Affiliation
    • American Association of Pharmaceutical Scientists (AAPS)
    • American Association for Cancer Research (AACR)
    • American Association of Colleges of Pharmacy (AACP)
    • Rho Chi Honor Society in Pharmacy (former student advisor)
    • Gulf Coast Consortia (GCC)
    • American Chemical Society (ACS)
    • Phi Lambda Upsilon Honorary Chemical Society
    Collapse webpage

    Collapse Research 
    Collapse research activities and funding
    U54MD007605     (LIANG, DONG ;OLALEYE, OMONIKE ARIKE ;XIE, HUAN)Sep 30, 1986 - May 31, 2025
    NIH
    Center for Biomedical and Minority Health Research
    Role: Co-Principal Investigator
    SC3GM102018     (XIE, HUAN)Sep 15, 2012 - Jul 31, 2018
    NIH
    Development of a Novel Nanoconstruct Based Photothermal Therapy for Tumor Hypoxia
    Role Description: This is a multi-institutional post-doctoral training program designed to prepare post-doctoral trainees for future careers in academic and/or commercial cancer therapeutics research and development.
    Role: Subaward PI
    RP180748     (Dong Liang)Sep 1, 2018 - Aug 30, 2023
    Cancer Prevention Research Institute of Texas (CPRIT)
    GCC Center for Comprehensive PK/PD and Formulation
    Role Description: provide a bridge to advance early translational cancer drug discovery through preclinical studies
    Role: Co-Principal Investigator
    RP210043     (Davies)Aug 1, 2021 - Jul 31, 2026
    Cancer Prevention Research Institute of Texas (CPRIT)
    Cancer Therapeutics Training Program (CTTP)
    Role Description: Goal: a multi-institutional post-doctoral training program designed to prepare post-doctoral trainees for future careers in academic and/or commercial cancer therapeutics research and development.
    Role: Subaward PI at TSU
         (Xie)Sep 1, 2022 - Aug 31, 2027
    NCI
    NCI Experimental Therapeutics (NExT) Program Chemical Biology Consortium (CBC)
    Role Description: Goal: to build the Institute of Drug Discovery and Development (iD3) at TSU and provide services for NCI-selected projects as NCI-designated sub-contractor
    Role: PI
    Collapse research resources
    This researcher has shared information about their research resources
    in the eagle-i Network. To update or add resource records, contact
    support@rtrn.net.
    Pharmacology Core

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Wang Y, Ma J, Lin SY, Xie H, Liang D. A stability indicating LC-MS/MS method for quantification of a NOX Inhibitor R14 in its bisulfite adduct form for pharmacokinetic studies. J Pharm Biomed Anal. 2023 May 10; 228:115326. PMID: 36924633.
      Citations:    Fields:    Translation:Animals
    2. Gupta R, Chen Y, Sarkar M, Xie H. Surfactant Mediated Accelerated and Discriminatory In Vitro Drug Release Method for PLGA Nanoparticles of Poorly Water-Soluble Drug. Pharmaceuticals (Basel). 2022 Nov 29; 15(12). PMID: 36558940.
      Citations:    
    3. Sarkar M, Wang Y, Ekpenyong O, Liang D, Xie H. Pharmacokinetic behaviors of soft nanoparticulate formulations of chemotherapeutics. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 03; 15(2):e1846. PMID: 35979879.
      Citations: 2     Fields:    Translation:Humans
    4. Wang Y, Xie H, Alugubelli YR, Ma Y, Xu S, Ma J, Liu WR, Liang D. Accurate Mass Identification of an Interfering Water Adduct and Strategies in Development and Validation of an LC-MS/MS Method for Quantification of MPI8, a Potent SARS-CoV-2 Main Protease Inhibitor, in Rat Plasma in Pharmacokinetic Studies. Pharmaceuticals (Basel). 2022 May 27; 15(6). PMID: 35745595.
      Citations:    
    5. Rincon Nigro ME, Du T, Gao S, Kaur M, Xie H, Olaleye OA, Liang D. Metabolite Identification of a Novel Anti-Leishmanial Agent OJT007 in Rat Liver Microsomes Using LC-MS/MS. Molecules. 2022 Apr 30; 27(9). PMID: 35566205.
      Citations: 4     Fields:    Translation:AnimalsCells
    6. Chen Y, Gao X, Gupta R, Ma J, Dere R, Liang D, Xie H. Development and Validation of an LC-MS/MS Method for AC1LPSZG and Pharmacokinetics Application in Rats. J Chromatogr Sci. 2022 Jan 01; 60(1):26-34. PMID: 33667297.
      Citations: 1     Fields:    Translation:Animals
    7. Gao X, Tsai RYL, Ma J, Wang Y, Liu X, Liang D, Xie H. Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats. Pharmaceuticals (Basel). 2021 Dec 31; 15(1). PMID: 35056109.
      Citations:    
    8. Gupta R, Chen Y, Xie H. In vitro dissolution considerations associated with nano drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 11; 13(6):e1732. PMID: 34132050.
      Citations: 7     Fields:    Translation:Cells
    9. Rincon Nigro M, Ma J, Awosemo OT, Xie H, Olaleye OA, Liang D. Development and Validation of a Sensitive, Specific and Reproducible UPLC-MS/MS Method for the Quantification of OJT007, A Novel Anti-Leishmanial Agent: Application to a Pharmacokinetic Study. Int J Environ Res Public Health. 2021 04 27; 18(9). PMID: 33925369.
      Citations: 1     Fields:    Translation:Animals
    10. Gao X, Wu L, Tsai RYL, Ma J, Liu X, Chow DS, Liang D, Xie H. Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. Pharmaceutics. 2021 Apr 17; 13(4). PMID: 33920640.
      Citations:    
    11. Ekpenyong O, Cooper C, Ma J, Guy NC, Payan AN, Ban F, Cherkasov A, Cox MB, Liang D, Xie H. Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer. Pharmaceuticals (Basel). 2020 Nov 13; 13(11). PMID: 33202977.
      Citations:    
    12. Wang Y, Ma J, Martinez ED, Liang D, Xie H. A UHPLC-MS/MS method for the quantification of JIB-04 in rat plasma: Development, validation and application to pharmacokinetics study. J Pharm Biomed Anal. 2020 Nov 30; 191:113587. PMID: 32892084.
      Citations:    Fields:    Translation:Animals
    13. Ekpenyong O, Gao X, Ma J, Cooper C, Nguyen L, Olaleye OA, Liang D, Xie H. Pre-Clinical Pharmacokinetics, Tissue Distribution and Physicochemical Studies of CLBQ14, a Novel Methionine Aminopeptidase Inhibitor for the Treatment of Infectious Diseases. Drug Des Devel Ther. 2020; 14:1263-1277. PMID: 32280198.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    14. Gao X, Tsai RYL, Ma J, Bhupal PK, Liu X, Liang D, Xie H. Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jan 01; 1136:121930. PMID: 31855839.
      Citations: 8     Fields:    Translation:Animals
    15. Ekpenyong O, Cooper C, Ma J, Liang D, Olaleye O, Xie H. A simple, sensitive and reliable LC-MS/MS method for the determination of 7-bromo-5-chloroquinolin-8-ol (CLBQ14), a potent and selective inhibitor of methionine aminopeptidases: Application to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Oct 15; 1097-1098:35-43. PMID: 30199748.
      Citations: 3     Fields:    Translation:Animals
    16. Chen Y, Bian X, Aliru M, Deorukhkar AA, Ekpenyong O, Liang S, John J, Ma J, Gao X, Schwartz J, Singh P, Ye Y, Krishnan S, Xie H. Hypoxia-targeted gold nanorods for cancer photothermal therapy. Oncotarget. 2018 May 29; 9(41):26556-26571. PMID: 29899876.
      Citations: 8     Fields:    
    17. Gupta R, Xie H. Nanoparticles in Daily Life: Applications, Toxicity and Regulations. J Environ Pathol Toxicol Oncol. 2018; 37(3):209-230. PMID: 30317972.
      Citations: 86     Fields:    Translation:HumansAnimals
    18. Joshi JB, Patel D, Morton DJ, Sharma P, Zou J, Hewa Bostanthirige D, Gorantla Y, Nagappan P, Komaragiri SK, Sivils JC, Xie H, Palaniappan R, Wang G, Cox MB, Chaudhary J. Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52. Mol Oncol. 2017 04; 11(4):337-357. PMID: 28252832.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    19. Liang S, Bian X, Liang D, Sivils JC, Neckers LM, Cox MB, Xie H. Solution formulation development and efficacy of MJC13 in a preclinical model of castration-resistant prostate cancer. Pharm Dev Technol. 2016; 21(1):121-6. PMID: 25380396.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    20. Liang S, Sanchez-Espiridion B, Xie H, Ma J, Wu X, Liang D. Determination of proline in human serum by a robust LC-MS/MS method: application to identification of human metabolites as candidate biomarkers for esophageal cancer early detection and risk stratification. Biomed Chromatogr. 2015 Apr; 29(4):570-7. PMID: 25164985.
      Citations: 12     Fields:    Translation:Humans
    21. Liang S, Bian X, Sivils J, Neckers LM, Cox MB, Xie H. Quantification of a New Anti-Cancer Molecule MJC13 Using a Rapid, Sensitive, and Reliable Liquid Chromatography-Tandem Mass Spectrometry Method. Am J Mod Chromatogr. 2014; 1(1):1-11. PMID: 25594071.
      Citations:    
    22. Bian X, Liang S, John J, Hsiao CH, Wei X, Liang D, Xie H. Development of PLGA-based itraconazole injectable nanospheres for sustained release. Int J Nanomedicine. 2013; 8:4521-31. PMID: 24311942.
      Citations: 8     Fields:    Translation:Animals
    23. John MK, Xie H, Bell EC, Liang D. Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. Anticancer Res. 2013 Oct; 33(10):4285-91. PMID: 24122994.
      Citations: 10     Fields:    Translation:Animals
    24. Xie H, Goins B, Bao A, Wang ZJ, Phillips WT. Effect of intratumoral administration on biodistribution of 64Cu-labeled nanoshells. Int J Nanomedicine. 2012; 7:2227-38. PMID: 22619558.
      Citations: 20     Fields:    Translation:HumansAnimalsCells
    25. Liang S, Bian X, Ma J, Arogunjo M, Deorukhkar AA, Krishnan S, Xie H. Development and validation of a sensitive LC/MS/MS method for the determination of ?-tocotrienol in rat plasma: application to pharmacokinetic studies. Biomed Chromatogr. 2013 Jan; 27(1):58-66. PMID: 22522964.
      Citations: 4     Fields:    Translation:Animals
    26. Xie H, Diagaradjane P, Deorukhkar AA, Goins B, Bao A, Phillips WT, Wang Z, Schwartz J, Krishnan S. Integrin av?3-targeted gold nanoshells augment tumor vasculature-specific imaging and therapy. Int J Nanomedicine. 2011; 6:259-69. PMID: 21423588.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    27. Xie, H.; Wang, Z.; Bao, A.; Goins, B.; Phillips, W.T. Nanoimaging - Biomedical Nanotechnology Book series. Radiolabeled Gold Nanoshells for In Vivo Imaging: Example of Methodology for Initial Evaluation of Biodistribution of a Novel Nanoparticle. 2011.
    28. Xie H, Wang ZJ, Bao A, Goins B, Phillips WT. In vivo PET imaging and biodistribution of radiolabeled gold nanoshells in rats with tumor xenografts. Int J Pharm. 2010 Aug 16; 395(1-2):324-30. PMID: 20540999.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    29. Xie H, Gill-Sharp KL, O'Neal DP. Quantitative estimation of gold nanoshell concentrations in whole blood using dynamic light scattering. Nanomedicine. 2007 Mar; 3(1):89-94. PMID: 17379173.
      Citations: 11     Fields:    Translation:Animals
    30. Tkachenko A, Xie H, Franzen S, Feldheim DL. Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging. Methods Mol Biol. 2005; 303:85-99. PMID: 15923677.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    31. Kr?mer S, Xie H, Gaff J, Williamson JR, Tkachenko AG, Nouri N, Feldheim DA, Feldheim DL. Preparation of protein gradients through the controlled deposition of protein-nanoparticle conjugates onto functionalized surfaces. J Am Chem Soc. 2004 May 05; 126(17):5388-95. PMID: 15113210.
      Citations: 6     Fields:    Translation:AnimalsCells
    32. Tkachenko AG, Xie H, Liu Y, Coleman D, Ryan J, Glomm WR, Shipton MK, Franzen S, Feldheim DL. Cellular trajectories of peptide-modified gold particle complexes: comparison of nuclear localization signals and peptide transduction domains. Bioconjug Chem. 2004 May-Jun; 15(3):482-90. PMID: 15149175.
      Citations: 72     Fields:    Translation:HumansAnimalsCells
    33. Xie H, Tkachenko AG, Glomm WR, Ryan JA, Brennaman MK, Papanikolas JM, Franzen S, Feldheim DL. Critical flocculation concentrations, binding isotherms, and ligand exchange properties of peptide-modified gold nanoparticles studied by UV-visible, fluorescence, and time-correlated single photon counting spectroscopies. Anal Chem. 2003 Nov 01; 75(21):5797-805. PMID: 14588020.
      Citations: 12     Fields:    Translation:AnimalsCells
    34. Tkachenko AG, Xie H, Coleman D, Glomm W, Ryan J, Anderson MF, Franzen S, Feldheim DL. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc. 2003 Apr 23; 125(16):4700-1. PMID: 12696875.
      Citations: 128     Fields:    Translation:HumansCells
    35. Chen X, Xie H, Kong J, Deng J. Characterization for didodecyldimethylammonium bromide liquid crystal film entrapping catalase with enhanced direct electron transfer rate. Biosens Bioelectron. 2001 Jan; 16(1-2):115-20. PMID: 11261846.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    Xie's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (165)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support